{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:09:14Z","timestamp":1779253754648,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic and bariatric surgery (MBS) is an established treatment for severe obesity, but its role in Asian patients with mild obesity (body mass index [BMI] 27.5-32.5 kg\/m\u00b2) remains controversial due to limited mid-term evidence. This study evaluated the \u22653-year outcomes of MBS in this population compared with patients with BMI \u226532.5 kg\/m\u00b2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the mid-term (\u22653 years) efficacy and safety of MBS in Asian patients with mild obesity, compared with those with BMI \u2265MIhe kg\/m\u00b2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, 26 patients with mild obesity and 76 matched patients with higher BMI underwent MBS between 2013 and 2020. Outcomes included percent total weight loss (%TWL), metabolic control, remission of obesity-related comorbidities, and postoperative complications. The primary composite endpoint was defined as glycated hemoglobin &amp;lt;6.5%, low-density lipoprotein cholesterol &amp;lt;2.6 mmol\/L, systolic blood pressure &amp;lt;130 mmHg, and homeostasis model assessment of insulin resistance &amp;lt;2.5 mmol\/L, \u03bcU\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At a mean follow-up of approximately 5 years, the mild obesity group achieved lower %TWL than the higher-BMI group (approximately 20% vs 26%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). Despite this, the rate of achieving the composite metabolic endpoint was comparable (30.7% vs 27.6%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.76). Both groups demonstrated sustained improvements in glycemic control, lipid profile, blood pressure, and insulin resistance. Remission of type 2 diabetes, hypertension, hyperuricemia, and metabolic-associated fatty liver disease increased significantly in both groups (all\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). Notably, a substantially greater proportion of patients in the obesity group achieved normalization of body weight (BMI &amp;lt;24 kg\/m\u00b2). Complication rates were low and comparable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In Asian patients, MBS appears safe and provides durable metabolic benefits across BMI categories. Despite losing less weight, those with mild obesity achieved similar cardiometabolic improvements and were more likely to reach a normal BMI. These findings are preliminary. Future research should prioritize large, multicenter studies focusing on the BMI 27.5\u201330 kg\/m\u00b2 subgroup without advanced metabolic disease, randomized trials comparing surgery with current pharmacotherapies, and long-term studies tracking hard cardiovascular endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1828283","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:39:57Z","timestamp":1779251997000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population"],"prefix":"10.3389","volume":"17","author":[{"given":"Wanying","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Branch of National Clinical Research Center for Metabolic Diseases","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Branch of National Clinical Research Center for Metabolic Diseases","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanhao","family":"Huang","sequence":"additional","affiliation":[{"name":"Branch of National Clinical Research Center for Metabolic Diseases","place":["Nanjing, China"]},{"name":"Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Affiliated Drum Tower Hospital, Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Branch of National Clinical Research Center for Metabolic Diseases","place":["Nanjing, China"]},{"name":"Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Affiliated Drum Tower Hospital, Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Tang","sequence":"additional","affiliation":[{"name":"Branch of National Clinical Research Center for Metabolic Diseases","place":["Nanjing, China"]},{"name":"Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Affiliated Drum Tower Hospital, Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Branch of National Clinical Research Center for Metabolic Diseases","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehui","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Metabolic and Bariatric Surgery, Affiliated Drum Tower Hospital, Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhuan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Branch of National Clinical Research Center for Metabolic Diseases","place":["Nanjing, China"]},{"name":"Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Affiliated Drum Tower Hospital, Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","volume-title":"World obesity atlas 2025","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0140-6736(21)00798-4","article-title":"Body-mass index and obesity in urban and rural China: Findings from consecutive nationally representative surveys during 2004-18","volume":"398","author":"Wang","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.12290\/xhyxzz.2024-0918","article-title":"Chinese guidelines for the clinical management of obesity (2024 edition)","volume":"16","year":"2025","journal-title":"Med J Peking Union Med Coll Hosp"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00045-0","article-title":"Epidemiology and determinants of obesity in China","volume":"9","author":"Pan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15238","article-title":"Prevalence of obesity and associated complications in China: A cross-sectional, real-world study in 15.8 million adults","volume":"25","author":"Chen","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032742","article-title":"Metabolically healthy obesity and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: A protocol for a systematic review and meta-analysis of prospective studies","volume":"9","author":"Tian","year":"2019","journal-title":"BMJ Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12916-020-01666-y","article-title":"The role of overweight and obesity in adverse cardiovascular disease mortality trends: An analysis of multiple cause of death data from Australia and the USA","volume":"18","author":"Adair","year":"2020","journal-title":"BMC Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The step 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The step 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"Jama"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00075-6","article-title":"Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial","volume":"386","author":"Mingrone","year":"2015","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society of Metabolic and Bariatric Surgery (Asmbs) and International Federation for the Surgery of Obesity and Metabolic Disorders (Ifso) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-Sint","article-title":"Introduction and methodology: Standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0318","article-title":"Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes","volume":"331","author":"Courcoulas","year":"2024","journal-title":"Jama"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn115610-2022091500523","article-title":"Chinese expert consensus on indications and management of metabolic surgery (2022 edition)","volume":"42","year":"2022","journal-title":"Chin J Pract Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: A review","volume":"324","author":"Arterburn","year":"2020","journal-title":"Jama"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01027-9","article-title":"Are Chinese patients with type 2 diabetes and a body mass index of 27.5-32.5 kg\/m(2) suitable for metabolic surgery? A one-year post-surgery study","volume":"12","author":"Zhang","year":"2021","journal-title":"Diabetes Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2021.11.019","article-title":"Effect of bariatric surgery versus medical therapy on long-term cardiovascular risk in low bmi Chinese patients with type 2 diabetes: A propensity score-matched analysis","volume":"18","author":"Ke","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2024.100145","article-title":"Metabolic surgery in Asian patients with type 2 diabetes mellitus and body mass index less than 30kg\/m2: A systematic review","volume":"12","author":"Osorio Manyari","year":"2024","journal-title":"Obes Pillars"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-014-1411-y","article-title":"Effect of Roux-en-Y gastric bypass with different pouch size in Chinese T2dm patients with bmi 30\u201335 kg\/m2","volume":"25","author":"Ren","year":"2015","journal-title":"Obes Surg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12893-015-0074-5","article-title":"Long-term effects of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass for the treatment of Chinese type 2 diabetes mellitus patients with body mass index 28\u201335 kg\/m(2)","volume":"15","author":"Yang","year":"2015","journal-title":"BMC Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12893","article-title":"Bariatric and metabolic surgery in Asia: Where are we, and where are we going","volume":"9","author":"Yasuda","year":"2018","journal-title":"J Diabetes Investig"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2234","article-title":"Dietary and nutritional approaches for prevention and management of type 2 diabetes","volume":"361","author":"Forouhi","year":"2018","journal-title":"Bmj-British Med J"},{"key":"B25","article-title":"Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition)","volume-title":"Beijing: people\u2019s medical publishing house","year":"2025"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.032380","article-title":"Status of hypertension in China results from the China Hypertension Survey, 2012-2015","volume":"137","author":"Wang","year":"2018","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 Esc\/Eas guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05751-w","article-title":"Hyperuricemia and clustering of cardiovascular risk factors in the Chinese adult population","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2024.00311","article-title":"Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024)","volume":"12","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2018.08.030","article-title":"Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: A case-matched study","volume":"89","author":"Fayad","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-025-08044-8","article-title":"Long-term outcomes in sleeve gastrectomy versus Roux-en-Y gastric bypass: A systematic review and meta-analysis of randomized trials","volume":"35","author":"Delgado","year":"2025","journal-title":"Obes Surg"},{"key":"B33","doi-asserted-by":"publisher","first-page":"O1","DOI":"10.1002\/oby.22719","article-title":"Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: Cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, the Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists","volume":"28","author":"Mechanick","year":"2020","journal-title":"Obes (Silv Spr)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/bf00280883","article-title":"Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.soard.2015.02.003","article-title":"Standardized outcomes reporting in metabolic and bariatric surgery","volume":"11","author":"Brethauer","year":"2015","journal-title":"Surg Obes Relat Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13748","article-title":"East Asian perspectives in metabolic and bariatric surgery","volume":"13","author":"Oh","year":"2022","journal-title":"J Diabetes Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-023-02295-x","article-title":"Metabolic and bariatric surgery in patients with class I obesity; a two-year follow-up","volume":"24","author":"Kermansaravi","year":"2024","journal-title":"BMC Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-018-4847-8","article-title":"Bariatric surgery versus lifestyle intervention in class I obesity: 7-10-year results of a retrospective study","volume":"43","author":"Vitiello","year":"2019","journal-title":"World J Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0350","article-title":"Bariatric\/metabolic surgery to treat type 2 diabetes in patients with a bmi <35 kg\/m2","volume":"39","author":"Cummings","year":"2016","journal-title":"Diabetes Care"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.929530","article-title":"Bile acids, gut microbiota and metabolic surgery","volume":"13","author":"Tu","year":"2022","journal-title":"Front Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf218","article-title":"From pathophysiology to novel approaches for obesity-associated hypertension","volume":"18","author":"Kanbay","year":"2025","journal-title":"Clin Kidney J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4513-y","article-title":"Metabolic surgery for the treatment of type 2 diabetes in obese individuals","volume":"61","author":"Cummings","year":"2018","journal-title":"Diabetologia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03893-3","article-title":"Macrovascular and microvascular outcomes of metabolic surgery versus Glp-1 receptor agonists in patients with diabetes and obesity","volume":"31","author":"Gasoyan","year":"2025","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2024.04.013","article-title":"Metabolic surgery results in greater metabolic benefits in patients who achieve healthy weight","volume":"20","author":"Shen","year":"2024","journal-title":"Surg For Obes Relat Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1828283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:40:11Z","timestamp":1779252011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1828283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":44,"alternative-id":["10.3389\/fendo.2026.1828283"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1828283","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1828283"}}